Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: unknown, P. 104603 - 104603
Published: Dec. 1, 2024
Language: Английский
Gynecologic Oncology, Journal Year: 2025, Volume and Issue: 193, P. 30 - 40
Published: Jan. 6, 2025
Language: Английский
Citations
7
Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(5), P. 651 - 664
Published: Sept. 1, 2024
The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) the cervix. She received six cycles perioperative adjuvant therapy, including three neoadjuvant therapy (NAT) and postoperative by combination dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m
Language: Английский
Citations
15
Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13
Published: Jan. 24, 2025
Exosomes, as key mediators of intercellular communication, have been increasingly recognized for their role in the oncogenic processes, particularly facilitating drug resistance. This article delves into emerging evidence linking exosomal lncRNAs to modulation resistance mechanisms cancers such ovarian, cervical, and endometrial cancer. It synthesizes current research findings on how these influence cancer cell survival, tumor microenvironment, chemotherapy efficacy. Additionally, review highlights potential therapeutic strategies targeting lncRNAs, proposing a new frontier overcoming By mapping interface resistance, this aims provide comprehensive understanding that could pave way innovative treatments improved patient outcomes female reproductive system cancers.
Language: Английский
Citations
1
Gynecologic Oncology, Journal Year: 2025, Volume and Issue: 194, P. 1 - 10
Published: Feb. 6, 2025
Language: Английский
Citations
0
Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155864 - 155864
Published: March 1, 2025
Language: Английский
Citations
0
Journal of Imaging, Journal Year: 2025, Volume and Issue: 11(4), P. 110 - 110
Published: April 3, 2025
Artificial intelligence (AI) has emerged as a transformative tool in placental pathology, offering novel diagnostic methods that promise to improve accuracy, reduce inter-observer variability, and positively impact pregnancy outcomes. The primary objective of this review is summarize recent developments AI applications tailored specifically histopathology. Current AI-driven approaches include advanced digital image analysis, three-dimensional reconstruction, deep learning models such GestAltNet for precise gestational age estimation automated identification histological lesions, including decidual vasculopathy maternal vascular malperfusion. Despite these advancements, significant challenges remain, notably dataset heterogeneity, interpretative limitations current algorithms, issues regarding model transparency. We critically address by proposing targeted solutions, augmenting training datasets with annotated artifacts, promoting explainable methods, enhancing cross-institutional collaborations. Finally, we outline future research directions, emphasizing the refinement algorithms routine clinical integration fostering interdisciplinary cooperation among pathologists, computational researchers, specialists.
Language: Английский
Citations
0
Frontiers in Genetics, Journal Year: 2025, Volume and Issue: 16
Published: April 7, 2025
The role of immunogenic cell death (ICD) in cervical cancer (CESC) is not well understood. This study sought to investigate the significance ICD CESC and establish an ICDRs prognostic model improve immunotherapy efficacy for patients with cancer. ICD-associated genes were screened at single-cell transcriptome levels based on AddModuleScore, single-sample gene set enrichment analysis (ssGSEA) weighted co-expression network (WGCNA) analysis. Immunogenic death-related features (ICDRs) constructed using multiple machine algorithms, evaluated training validation sets provide quantitative tools predicting prognosis clinical practice. Predictive models used risk subgroups response immunotherapy, as drug sensitivity. Finally, expression ICD-related was verified by RT-qPCR. Through integrated data, transcriptomic profiling, computational modeling, seven identified highly patients. Multivariate demonstrated that low-risk had significantly better overall survival compared high-risk patients, confirming independent tool. Assessments tumor microenvironment (TME), mutation characteristics, sensitivity within indicated a stronger group.
Language: Английский
Citations
0
The Journal of Pathology, Journal Year: 2025, Volume and Issue: unknown
Published: April 14, 2025
Abstract Tumor protein p53 mutated/abnormal (p53abn) endometrial carcinomas account for over 50% of deaths but comprise only 15% all carcinomas. Most patients show limited response to standard‐of‐care chemotherapy with or without radiotherapy, and a minority cases are amenable targeted therapies like poly‐ADP ribose polymerase (PARP) inhibitors HER2‐directed therapies. Recent immunotherapy clinical trials have demonstrated remarkable efficacy, not in mismatch repair deficient (MMRd) tumors also subset repair‐proficient (MMRp) tumors. However, the immune microenvironment its relationship other therapeutic targets MMRp carcinoma remains poorly understood. Here, we characterize p53abn carcinoma, most clinically aggressive subtype correlate antitumor signatures targetable alterations. We accrued 256 treatment‐naïve systemically profiled T‐cell, B‐cell, myeloid, tumor‐cell populations multiplex immunofluorescence assess tissue localization functional status cells. Shallow whole‐genome sequencing was performed on 126 cases. Patterns infiltration were compared survival outcomes mutational signatures. Mixture modeling divided into tumor‐infiltrating lymphocyte (TIL)‐rich TIL‐poor subsets. Over TIL‐rich. TIL‐rich overexpressed evasion molecules associated longer overall disease‐specific multivariate analysis. This effect particularly pronounced advanced stage disease who did receive adjuvant chemotherapy. TIL associate homologous recombination HER2 amplification. Our findings demonstrate biological rationale substantial cancer may help inform combination checkpoint inhibition, PARP inhibitors, anti‐HER2 agents. © 2025 The Author(s). Journal Pathology published by John Wiley & Sons Ltd behalf Pathological Society Great Britain Ireland.
Language: Английский
Citations
0
ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(8), P. 2215 - 2236
Published: July 3, 2024
This Review explores how tumor-associated regulatory cells (Tregs) affect cancer immunotherapy. It shows Tregs play a role in keeping the immune system check, cancers grow, and well immunotherapy work. use many ways to suppress system, these are affected by tumor microenvironment (TME). New approaches therapy showing promise, such as targeting Treg checkpoint receptors precisely using Fc-engineered antibodies. is important tailor treatments each patient's TME order provide personalized care. Understanding biology essential for creating effective improving long-term outcomes of
Language: Английский
Citations
2
Current Oncology, Journal Year: 2024, Volume and Issue: 31(9), P. 5374 - 5383
Published: Sept. 12, 2024
Endometrial cancer (EC) is a common gynecologic malignancy with rising incidence due to obesity, comorbid conditions, and related lifestyle factors. The standard of care for primary disease consists surgical resection with/without chemotherapy ± radiotherapy select patients. Recurrence in patients advanced-stage and/or high-risk features, who primarily are treated systemic therapy. identification novel targets malignant EC has led the development wide-range inhibitors. Abemaciclib an orally active unique cyclin-dependent kinase (CDK) inhibitor, selective CDK4 CDK6 cell cycle pathways. This agent potential anti-neoplastic activity indicated combination various therapies such as endocrine therapy, aromatase inhibitors, hormone therapies, breast (BC). Herein, we sought summarize biochemical/pharmacological properties abemaciclib its therapeutic EC. While role(s) was fairly established subset advanced/metastatic BC through pivotal MONARCH trials, attributes clinical utility limited. Thus, based on some promising pre-clinical/translational insights recent phase II study, highlight abemaciclib's usefulness EC, particularly recurrent estrogen-receptor-positive cases.
Language: Английский
Citations
2